IRISH CLINICAL ONCOLOGY RESEARCH GROUP LIMITED LBG -  

Ranking results:

Past rankings:

2018
Criterium:Position:
Overall Score:> 1000
Total Project Funding per Partner:> 1000
Total Number of Projects:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000

Ranking timeline:

Project Participation Performance(2012-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:

Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2017 0 3.836.772 0 1
2012 0 5.999.156 277.200 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:Projects [No]:
ROYAL COLLEGE OF SURGEONS IN IRELAND2
VIB2
AGILENT TECHNOLOGIES BELGIUM NV1
BMS FRANCE1
CARTHERA1
CHAMPIONS ONCOLOGY INC1
EPIGENOMICS1
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM1
GENEXPLAIN1
INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE1
INSILICO BIOTECHNOLOGY1
INSTITUT DU CERVEAU ET DE LA MOELLE EPINIERE1
INTERNATIONAL BRAIN TUMOUR ALLIANCE1
KATHOLIEKE UNIVERSITEIT LEUVEN1
LUXEMBOURG INSTITUTE OF HEALTH1
MEDIZINISCHE HOCHSCHULE HANNOVER1
MIMETAS BV1
ONCOMARK LIMITED1
ONCURIOUS NV1
PEPSCOPE BV1
PINTAIL1
RUPRECHT KARLS UNIVERSITAET HEIDELBERG1
SOMANTIX BV1
STICHTING VU1
TEVA PHARMACEUTICALS EUROPE BV1
UNIVERSITAET STUTTGART1
UNIVERSITE DU LUXEMBOURG1
UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND DUBLIN1
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG1
YUMAB1

Constancy:

Total number of partners: 32
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 32
Frequent / Rare Partner Ratio: 0

Project overview:

Start dateProjectacronymrolefundingpartners
2017-09-01Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics GLIOTRAINparticipant3.836.77223
2012-02-01Predictive Genomic Biomarkers Methods for Combination Bevacizumab (Avastin) Therapy in Metastatic Colorectal Cancer ANGIOPREDICTparticipant5.999.15611